Stay updated with breaking news from Daniel Burkhoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
First-in-human snapshots, pilot studies, roll-in cohorts, and post-hoc analyses showcase diverse technologies, but few certainties.
Wearable causes excess fluids to be sweated out and evaporated on the skin without discomfort, using very low humidity and fast flowing air.